Skip to main content

Table 1 Baseline Characteristics

From: Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

  No. (%)
Total N 152 (100)
Median age (range), years 61 (21–82)
Sex
 Male 72 (47%)
 Female 80 (53%)
Performance status
 ECOG 0–1 149 (98%)
 ECOG ≥2 3 (2%)
Subtypes
 Acral 58 (38%)
 Mucosal 47 (31%)
 Cutaneous 36 (24%)
 Uveal 4 (2%)
 Other (unclassifiable) 7 (5%)
M staging of extent of metastasis
 M0 23 (15%)
 M1a 38 (25%)
 M1b 38 (25%)
 M1c 42 (28%)
 M1d 11 (7%)
BRAFV600 status (n = 133)
 Mutant 23/133 (17%)
 Wildtype 110/133 (83%)
KIT status (n = 98)
 Mutant 14/98 (14%)
 Wildtype 84/98 (86%)
Lactate dehydrogenase concentration
 Normal 101 (66%)
 Elevated 32 (21%)
 Unknown 19 (13%)
Number of lines of previous systemic therapies
 0 96 (63%)
 1 28 (18%)
 2 22 (15%)
 ≥3 6 (4%)
Type of previous treatment
 Ipilimumab 17 (11%)
 Interleukin-2 2 (1%)
 BRAF/MEK inhibitor 6 (4%)
 Cytotoxic chemotherapy 45 (30%)
\